This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hawk, E. Articles by Graubard, B. I. Search for Related Content PubMed PubMed Citation Articles by Hawk, E. Articles by Graubard, B. I.

Male Pattern Baldness and Clinical Prostate Cancer in the Epidemiologic Follow-Up of the First National Health and Nutrition Examination Survey

Gastrointestinal and Other Cancer Research Group, Division of Cancer Prevention, [E. H.], Applied Research Branch, Division of Cancer Control and Population Science [R. A. B.], and Biostatistics Branch, Division of Cancer Epidemiology and Genetics [B. I. G.], National Cancer Institute, NIH, Bethesda, Maryland 20892

Male pattern baldness (MPB) and prostate cancer are common in American males; however, MPB is clinically observable decades earlier. Aging, androgens, and heritability are risk factors for both conditions. We prospectively studied the association between MPB and clinical prostate cancer in a cohort representative of the United States male population. A total of 4,421 men 25–75 years old without a history of prostate cancer were examined for baldness in the Epidemiologic Follow-up Study of the first National Health and Nutrition Examination Survey. Participants were followed from baseline (1971–1974) through 1992. Incident cases of prostate cancer were identified by interviews, medical records, and death certificates. Age-standardized incidence rates and proportional hazards models were used to examine the association between MPB and clinical prostate cancer. Prostate cancer was diagnosed in 214 subjects over 17–21 years of follow-up. The age-standardized incidence of prostate cancer was greater among men with baldness at baseline (17.5 versus 12.5 per 10,000 person-years). The adjusted relative risk for prostate cancer among men with baldness was 1.50 (95% confidence interval, 1.12–2.00) and was similar regardless of the severity of baldness at baseline and was independent of other risk factors, including race and age. MPB seems to be a risk factor for clinical prostate cancer.

This article has been cited by other articles:

				S. Bhasin, A. B. Singh, R. P. Mac, B. Carter, M. I. Lee, and G. R. Cunningham Managing the Risks of Prostate Disease During Testosterone Replacement Therapy in Older Men: Recommendations for a Standardized Monitoring Plan J Androl, May 1, 2003; 24(3): 299 - 311. [Full Text] [PDF]

				G. G. Giles, G. Severi, R. Sinclair, D. R. English, M. R. E. McCredie, W. Johnson, P. Boyle, and J. L. Hopper Androgenetic Alopecia and Prostate Cancer: Findings from an Australian Case-Control Study Cancer Epidemiol. Biomarkers Prev., June 1, 2002; 11(6): 549 - 553. [Abstract] [Full Text] [PDF]

				W. Demark-Wahnefried, J. M. Schildkraut, E. Hawk, B. I. Graubard, and R. A. Breslow Correspondence re: E. Hawk, et al., Male Pattern Baldness and Clinical Prostate Cancer in the Epidemiologic Follow-Up of the First National Health and Nutrition Examination Survey. Cancer Epidemiol.Biomark. Prev., 9: 523-527, 2000 Cancer Epidemiol. Biomarkers Prev., April 1, 2001; 10(4): 415 - 416. [Full Text]